Muscle wasting in cirrhosis, known clinically as sarcopenia, sets off a cascade of problems that go well beyond looking thin or feeling weak. Once skeletal muscle mass drops significantly, people with cirrhosis face shorter survival on transplant waiting lists, higher rates of hepatic encephalopathy, greater vulnerability to kidney injury, and a diminished ability to recover from infections or surgeries.1PubMed Central. Clinical relevance of sarcopenia in patients with cirrhosis The good news is that the process is not entirely irreversible, but reversing it requires understanding why it happens and what tools actually work.
Why Cirrhosis Eats Away at Muscle
A healthy liver clears ammonia from the blood by converting it to urea. When the liver is severely scarred, that cleanup system fails, and ammonia builds up in the bloodstream. Skeletal muscle becomes the body’s backup ammonia-disposal system, but the cost is steep. Elevated ammonia triggers a chain of molecular events inside muscle cells: it ramps up production of a protein called myostatin, which acts as a brake on muscle growth. Myostatin in turn suppresses the signaling pathway that drives new protein synthesis while simultaneously ramping up autophagy, the process by which cells break down their own components for fuel.2PubMed Central. Hyperammonemia and proteostasis in cirrhosis The result is that muscle is being dismantled faster than it can be rebuilt.
On top of this, cirrhosis scrambles the balance of amino acids in the blood. Branched-chain amino acids, which muscle tissue depends on for repair and energy, drop relative to other amino acids. That ratio shift worsens as liver dysfunction progresses and is itself linked to poorer outcomes.3PubMed Central. Clinical and Therapeutic Implications of BCAAs Metabolism during Chronic Liver Disease in Humans: Crosstalk between Skeletal Muscle and Liver Hormonal disruption compounds the problem further. Up to 90 percent of men with cirrhosis have reduced testosterone levels, and those levels fall as liver disease advances. Testosterone is one of the body’s main anabolic signals for muscle, bone, and red blood cell production, so its decline accelerates muscle loss and contributes to fatigue, osteoporosis, and other features of advanced liver disease.4PubMed. Testosterone in men with advanced liver disease: abnormalities and implications
How Muscle Loss Changes the Course of Liver Disease
Sarcopenia does not just coexist with cirrhosis; it actively makes the disease more dangerous. In a national cohort of 585 liver transplant candidates, roughly 43 percent were sarcopenic, and those patients had significantly shorter survival on the waiting list. The effect was especially pronounced among patients whose overall liver disease scores were relatively low, meaning that muscle loss added a risk that standard scoring systems failed to capture.5PubMed. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort In other words, two patients with the same liver function scores could face very different odds of surviving the wait for a new organ, depending on how much muscle they had left.
The connection between muscle loss and hepatic encephalopathy, the episodes of confusion, personality change, and impaired concentration common in advanced cirrhosis, is tightly bound to the ammonia problem. Muscle tissue is the primary extrahepatic site for ammonia metabolism. When there is less muscle to absorb and process ammonia, blood ammonia levels climb higher, which worsens brain fog and raises the risk of full-blown encephalopathy episodes.6PubMed Central. Ammonia and the Muscle: An Emerging Point of View on Hepatic Encephalopathy This creates a vicious cycle: ammonia drives muscle loss, and muscle loss reduces the body’s capacity to clear ammonia.
Beyond encephalopathy, sarcopenia has been linked to a higher rate of acute kidney injury episodes. A pilot study of patients with decompensated cirrhosis found that sarcopenic patients experienced significantly more kidney injury episodes compared to those without sarcopenia, even though both groups had similar liver disease severity scores.7PubMed Central. Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis Kidney problems in cirrhosis are already common and often serious, so any additional vulnerability matters.
The Hidden Version of Muscle Wasting
One of the more insidious aspects of sarcopenia in cirrhosis is that it can be difficult to see. Many people with advanced liver disease retain large volumes of fluid as ascites (in the abdomen) and peripheral edema (in the legs). That fluid can mask dramatic muscle loss, making a patient appear normal weight or even overweight while their actual lean mass is dangerously low. Standard bedside tools like body-mass index and bioelectrical impedance readings are thrown off by this fluid overload, so clinicians sometimes miss the severity of the problem.8PubMed Central. Assessment of Malnutrition, Sarcopenia and Frailty in Patients with Cirrhosis: Which Tools Should We Use in Clinical Practice? Cross-sectional imaging, typically a CT scan at the level of the third lumbar vertebra, has become the reference standard for measuring muscle area in this population. But CT scans are not done for the sole purpose of muscle assessment, so sarcopenia often goes undetected until imaging is ordered for another reason.
This diagnostic blind spot is especially relevant for a condition called sarcopenic obesity, where a patient has both low muscle mass and high fat mass. In one study of cirrhosis patients awaiting liver transplant, those whose cirrhosis was caused by nonalcoholic steatohepatitis (NASH) were about six times more likely to have sarcopenic obesity than patients with other causes of cirrhosis.9PubMed Central. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation These patients look heavy but are functionally frail, and that combination is easy to overlook if nobody is measuring muscle directly.
Nutritional Strategies That Actually Help
People with cirrhosis burn through their glycogen stores abnormally fast overnight, so by morning their bodies are running on muscle protein and fat in a way that resembles prolonged starvation. This makes the timing of meals just as important as their content. A late evening snack, consumed after dinner but before bed, has emerged as one of the simplest and most consistently supported interventions for muscle wasting in cirrhosis. Research shows that this nighttime snack decreases fat burning and improves nitrogen balance, a marker that the body is building more protein than it is breaking down. Importantly, the same calories consumed during the day instead of at night did not produce the same benefit.10PubMed. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis
A systematic review and meta-analysis confirmed these effects more broadly: patients who ate a late evening snack shifted their fuel usage significantly, burning more carbohydrate and less fat, suggesting the catabolic state was partially reversed.11PubMed Central. Effects of Late Evening Snack on Cirrhotic Patients: A Systematic Review and Meta-Analysis The snack does not need to be anything exotic. A mix of complex carbohydrates and protein, around 200 calories, eaten within a couple of hours before sleep is the general approach.
Branched-chain amino acid supplements are the other widely studied nutritional intervention. Because cirrhosis depletes these specific amino acids, supplementation aims to restore the raw materials muscles need for repair. Reviews of the evidence suggest that supplementation shows positive effects on muscle mass, strength, and overall nutritional status in cirrhosis management.3PubMed Central. Clinical and Therapeutic Implications of BCAAs Metabolism during Chronic Liver Disease in Humans: Crosstalk between Skeletal Muscle and Liver Some clinicians combine these supplements with the late evening snack, using a BCAA-enriched formula as the bedtime meal itself.
Exercise in Cirrhosis Is Safer Than Most People Think
There has long been a concern that exercise in cirrhosis patients could increase portal pressure, the high blood pressure in the veins around the liver that causes serious complications like variceal bleeding. That worry has kept many patients sedentary and has made some clinicians hesitant to recommend physical activity. The evidence, however, tells a different story. Recent studies indicate that long-term exercise actually decreases portal pressure, and no aerobic exercise trials have reported increased serious adverse events in people with cirrhosis. A randomized trial of resistance training found no difference in adverse events between exercisers and controls, and the only deaths occurred in the control group.12Clinical Gastroenterology and Hepatology. Resistance Training Increases Muscle Strength and Muscle Size in Patients With Liver Cirrhosis
Both aerobic and resistance training have shown benefits for markers of sarcopenia, cardiorespiratory fitness, and quality of life. A review of exercise interventions concluded that these programs are safe even in patients with decompensated cirrhosis, the more advanced stage where complications like ascites and encephalopathy are present.13Current Treatment Options in Gastroenterology. Exercise Interventions for Cirrhosis The practical challenge is that fatigue, ascites, and general frailty make exercise difficult to start and sustain. Supervised programs, even modest ones like walking combined with light resistance bands, tend to have better adherence than unsupervised regimens.
Ammonia-Lowering Therapy as a Muscle Treatment
Because ammonia is a central driver of muscle breakdown in cirrhosis, researchers have tested whether lowering ammonia levels can reverse the process. In animal models, four weeks of ammonia-lowering therapy produced significant improvements: lean body mass increased, grip strength improved, muscle fiber diameter grew, and the molecular markers of muscle breakdown returned toward normal. The elevated myostatin, the suppressed protein synthesis signaling, and the increased autophagy that characterize hyperammonemic muscle were all reversed by treatment.14PubMed Central. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis
One ammonia-lowering agent that has gained attention specifically for its dual role is L-ornithine L-aspartate (LOLA), already in clinical use for hepatic encephalopathy. LOLA works by stimulating both urea synthesis in remaining functional liver cells and glutamine synthesis in muscle. Clinical data suggest that treating cirrhotic patients with LOLA limits ammonia-driven sarcopenia by improving muscle protein synthesis and function.15PubMed Central. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle The appeal of this approach is that it addresses the root cause rather than just the symptom, and any agent that simultaneously reduces encephalopathy risk and muscle loss offers a two-for-one benefit in a population that needs both.
When TIPS Placement Reverses Muscle Loss
A transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that creates a channel inside the liver to reroute blood flow and reduce portal pressure. It is typically performed to manage refractory ascites or recurrent variceal bleeding, not to treat sarcopenia specifically. But an interesting secondary finding has emerged: TIPS placement often leads to measurable gains in muscle mass.
In one study, patients saw a significant increase in core muscle area by six months after TIPS, even though their overall body weight dropped (because they were losing fluid). By 12 months, all imaging-based muscle measurements, including both primary and secondary muscle groups, were significantly higher than at baseline.16Journal of the Formosan Medical Association. Effects of transjugular intrahepatic portosystemic shunt on abdominal muscle mass in patients with decompensated cirrhosis A larger study showed similar results, with sarcopenic men gaining about 17 percent on a standardized muscle index at five months after TIPS, and sarcopenic women gaining about 20 percent over the same period.17PubMed. Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement
A systematic review and meta-analysis pooling data across multiple studies estimated that about 57 percent of sarcopenic patients improved after TIPS.18PubMed Central. Outcomes after TIPS in patients with cirrhosis and sarcopenia: A systematic review and meta-analysis The mechanism likely involves reduced portal pressure allowing better nutrient absorption from the gut, less ascites-related compression and inflammation, and potentially improved hormonal signaling. TIPS is not a treatment for sarcopenia per se, and it carries its own risks including encephalopathy, but the muscle gains are a welcome side benefit for patients who need the procedure for other reasons.
What Happens After Liver Transplant
Many patients and their families assume that a successful liver transplant will resolve sarcopenia along with everything else. The reality is more complicated. In the months immediately following transplant, muscle mass often drops further rather than recovering. Low serum albumin before the transplant, high-dose steroid immunosuppression afterward, and prolonged post-transplant hospitalization are all risk factors for additional lean mass loss in the early recovery period.19PubMed Central. Posttransplant Sarcopenia: An Underrecognized Early Consequence of Liver Transplantation
The longer-term picture introduces another concern. As the new liver restores metabolic function and appetite, patients often gain weight rapidly, but much of that weight may be fat rather than muscle. One study found that sarcopenic obesity was present in 88 percent of living-donor liver transplant recipients, while metabolic syndrome, including new-onset diabetes, high triglycerides, and hypertension, was present in over half. The prevalence of diabetes more than doubled from before to after transplant, jumping from 20 percent to 56 percent.20PubMed Central. Sarcopenic obesity with metabolic syndrome: a newly recognized entity following living donor liver transplantation In other words, transplant fixes the liver, but it can trade one metabolic problem for another if muscle mass is not actively rebuilt in the recovery period.
Putting Interventions Together in Practice
No single intervention reliably reverses sarcopenia in cirrhosis on its own. The patients who do best tend to be managed with a combination of strategies. A late evening snack addresses the overnight catabolic window. Branched-chain amino acid supplementation restores depleted building blocks. Ammonia-lowering medications, whether lactulose, rifaximin, or LOLA, target the molecular driver of muscle breakdown. Resistance and aerobic exercise provide the mechanical stimulus muscles need to actually grow. And when procedures like TIPS are indicated for portal hypertension complications, they may provide a metabolic environment more favorable to muscle recovery.
One of the biggest practical barriers is that sarcopenia often goes unrecognized until it is advanced. Fluid retention masks the visual cues, standard nutritional screening tools underperform in this population, and clinical attention tends to focus on liver-specific complications rather than body composition. By the time muscle loss is identified, the patient may already be frail enough that starting an exercise program or maintaining adequate nutrition is a genuine struggle. Earlier screening, ideally using imaging when CT scans are obtained for other purposes, gives clinicians a chance to intervene while the patient still has enough reserve to respond to treatment.
Testosterone and Other Hormonal Gaps
The hormonal dimension of cirrhosis-related muscle wasting extends beyond testosterone, but testosterone is the most studied and most dramatically affected. With levels reduced in up to 90 percent of men with cirrhosis, and levels declining further as liver disease progresses, the anabolic signal muscle needs to maintain itself is severely blunted.4PubMed. Testosterone in men with advanced liver disease: abnormalities and implications Many features of advanced cirrhosis in men, including muscle loss, osteoporosis, breast tissue enlargement, and reduced libido, overlap substantially with the features of low testosterone in otherwise healthy men. This overlap has prompted interest in testosterone replacement as a potential treatment, but the evidence remains thin and complicated by the fact that the liver metabolizes sex hormones. Giving exogenous testosterone to someone with severe liver dysfunction carries risks including worsening fluid retention and potentially stimulating liver tumor growth in patients with hepatocellular carcinoma. Clinical trials in this area have been small, and no major guidelines currently recommend routine testosterone replacement for sarcopenia in cirrhosis.
Growth hormone and insulin-like growth factor 1 are also suppressed in cirrhosis, contributing to the impaired anabolic environment. These deficiencies are understood as contributors to the problem, but therapeutic correction in the setting of liver disease remains investigational. For now, the hormonal aspect of cirrhosis-related sarcopenia is best understood as part of the explanation for why muscle is so hard to rebuild, rather than as a target where effective treatments currently exist.